Latest Administration News

Zimi Limited has completed production of its Smoke Connect safety range, progressed Matter Connect certification, and moved Senoa manufacturing to a new facility, while engaging investors for a capital raise.

DataWorks Group reports a dramatic reduction in cash outflows and rising revenues, driven by strong contract execution and cost discipline, setting the stage for positive operating cash flow by December 2025.

Asian Battery Metals has confirmed significant extensions of massive sulphide zones and high-grade mineralisation at its Oval Cu-Ni-PGE discovery in Mongolia, setting the stage for follow-up drilling and metallurgical testing in the coming quarter.

Orpheus Uranium Limited reported a net cash outflow from operations and investing in the June quarter but strengthened its cash position through financing activities, extending its funding runway to over seven quarters.

Talga Group has cemented its position in the European battery materials sector by securing full mining rights for its Nunasvaara South graphite mine and signing a binding supply agreement with fast-charging battery pioneer Nyobolt.

Bowen Coking Coal Limited remains suspended from ASX trading following its failure to update on funding and debt plans, compounded by the appointment of voluntary administrators.

Citigold Corporation Limited reports steady progress in exploration and mine design at its Charters Towers Gold Project, while actively pursuing funding partnerships to restart operations.

Income Asset Management has sold its term deposit broking business to Perpetual Corporate Trust, streamlining operations and securing significant cost savings while ensuring client continuity.

CAQ Holdings reported a significant 35% decline in leasing revenue for the June 2025 quarter amid tenant contract changes and high vacancy rates. The company is optimistic about a turnaround following new customs policies in Hainan Free Trade Port set to take effect in December.

White Cliff Minerals confirms significant high-grade copper and silver mineralisation at its Danvers prospect, raising A$14.4 million to fund expanded exploration. The company also announces a strategic board appointment as it advances its Rae Copper and Great Bear projects.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.